GSK plc Reports Share Transaction in August 2025
Ticker: GLAXF · Form: 6-K · Filed: Aug 11, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Aug 11, 2025 |
| Risk Level | low |
| Pages | 10 |
| Reading Time | 12 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-transaction, 6-K, disclosure
TL;DR
GSK bought/sold its own shares in August 2025, filing a 6-K.
AI Summary
GSK plc announced on August 11, 2025, that it has completed a transaction involving its own shares. The filing, a Form 6-K, is a report of a foreign private issuer for the month of August 2025, detailing this share transaction.
Why It Matters
This filing indicates GSK plc's activity in managing its own stock, which can be relevant for investors tracking share buybacks or other corporate actions affecting outstanding shares.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of share transactions and does not contain information suggesting immediate financial risk.
Key Players & Entities
- GSK plc (company) — Registrant
- 001-15170 (company) — SEC File Number
- 20250811 (date) — Filing Date
FAQ
What type of transaction did GSK plc conduct with its own shares?
The filing indicates a 'Transaction in own shares' by GSK plc.
When was this transaction reported?
The transaction was reported in a Form 6-K filed on August 11, 2025, for the month of August 2025.
What is the SEC file number for GSK plc?
GSK plc's SEC file number is 001-15170.
What is the principal executive office address of GSK plc?
The principal executive office address is 79 New Oxford Street, London, WC1A 1DG.
Does GSK plc file annual reports under Form 20-F or Form 40-F?
GSK plc indicates it files annual reports under cover of Form 20-F.
Filing Stats: 2,885 words · 12 min read · ~10 pages · Grade level 3.6 · Accepted 2025-08-11 06:45:11
Filing Documents
- a6863u.htm (6-K) — 5759KB
- 0001654954-25-009310.txt ( ) — 5760KB
From the Filing
IN OWN SHARES a6863u     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934       For the month of August 2025   Commission File Number 001-15170     GSK plc (Translation of registrant's name into English)     79 New Oxford Street, London, WC1A 1DG (Address of principal executive office)       Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F . . . .X. . . . Form 40-F . . . . . . . .                                         Transaction in own shares   GSK plc (the " Company ") announces today   acting through its corporate stockbroker, Merrill Lynch International (the " Broker "), it has purchased the following number of the Company's ordinary shares of  31¼  pence each.   Date of purchase:   08 August 2025   Aggregate number of ordinary shares of  31¼  pence each purchased:   497,923   Lowest price paid per share (GBp):   1,389.50p   Highest price paid per share (GBp):   1,405.50p   Volume-weighted average price paid per share (GBp):   1,397.58p     The purchased shares will be held as Treasury shares.   Such purchase forms part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker on 4 June 2025, as announced on 4 June 2025. Since 4 June 2025 the Company has purchased 21,908,567 ordinary shares.   Following the above purchase, the Company will hold 240,042,950 ordinary shares in treasury and have 4,075,348,296 ordinary shares in issue (excluding Treasury shares).   The total number of voting rights in the Company is   4,075,348,296. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.   The Company confirms that, in accordance with DTR 5.5.1R, following the above purchase the percentage of voting rights attributable to the ordinary shares held in treasury is   5.89 per cent.   The table below contains detailed information of the individual trades made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) as part of the buyback programme.     Schedule of Purchases   Shares purchased:      GSK plc (ISIN: GB00BN7SWP63)   Date of purchases:     08 August 2025   Investment firm:          Merrill Lynch International     Aggregated information per trading venue:   Venue   Number of ordinary shares purchased   Highest price paid (per ordinary share) (GBp)   Lowest price paid (per ordinary share) (GBp)   Volume weighted average price paid (per ordinary share) (GBp)   London Stock Exchange (XLON)   497,923   1,405.50p   1,389.50p   1,397.58p   CBOE (CHIX)   0   -   -   -   CBOE (BATE)   0   -   -   -       Individual transactions:   Number ofShares   Price per Share (GBp)   Tradingvenue   Date oftransaction   Time oftransaction   Transaction reference number   11   1,401.00    XLON   08-Aug-2025   08:01:12   0XL0610000000000DDPCC9   12   1,401.00    XLON   08-Aug-2025   08:01:12   0XL06D0000000000DDPCL7   12   1,401.50    XLON   08-Aug-2025   08:01:12   0XL0610000000000DDPCC4   12   1,401.50    XLON   08-Aug-2025   08:01:12   0XL0614000000000DDPCH3   222   1,401.00    XLON   08-Aug-2025   08:01:12   0XL06A0000000000DDPCP1   298   1,401.00    XLON   08-Aug-2025   08:01:12   0XL0611000000000DDPCM4   38